The gene encoding a highly immunogenic mycobacterial heat-shock protein (hsp65) was transfected into the murine macrophage tumor cell line J774. The resulting hsp65-expressing cells 0774-hsp65) were no longer able to produce tumors in syngeneic mice. This loss of tumorigenicity was not mediated through T cells since the transfected cells did not produce tumors in atbymic mice. If mice are :first immunized with the J774-hsp65 cells and then challenged with the parent J774 cells, the mice do not develop tumors, indicating that the presence of the mycobacterial hsp65 protein greatly enhances immunological recognition of unique structures expressed by the parent tumor cells. This is further confirmed by the demonstration in vitro of T cells derived from J774-hsp65-immunized mice that are cytotoxic for the parent J774 cells. The results provide the basis for a novel strategy for enhancing the immunological recognition and decreasing the tumorigenicity of transformed cells.
H
'eat-shock proteins (hsp's) are molecular chaperones, medi-9 ating the assembly and folding of other proteins (1) (2) (3) (4) (5) . They have been reported to be expressed at abnormal levels in tumor cells (6) (7) (8) (9) , and in a murine sarcoma model, the tumor-specific antigen has been shown to be a hsp (10) . They are among the most immunogenic molecules known (11) (12) (13) (14) . The cause of this immunodominance is thought to reside in their universal distribution and high degree of sequence conservation, resulting in continuous priming of the immune system. Mycobacterial hsp's have been used as carder molecules for circumventing the need for adjuvants to greatly enhance immune responses to unrelated antigens (15, 16) .
Although spontaneously arising tumors are usually very weakly antigenic, their recognition by cytotoxic T cells and elimination in vivo can be greatly enhanced if they are engineered to express cytokine genes such as IL-2 (17) or IL-4 (18) . Thus, such cells must express unique structures that can be targets for immunological recognition. In an alternative approach to enhance specific immunity to tumor cells, we have transfected a highly malignant macrophage tumor cell line with the mycobacterial 65-kD hsp-encoding gene (hsp65). We find that not only do hsp65-expressing tumor cells lose their tumorigenicity in mice, but immunization of mice with the transfected cells induces strong T cell-mediated cytotoxic responses against the parent untransfected cells, and such mice are protected against challenge with the parent cells. The transfer of cytokine genes for cancer therapy has been widely reported, and in some cases has reached the stage of clinical trials (19, 20) ; transfer of the mycobacteria165-kD hsp gene to tumor cells represents a novel strategy for an immunotherapeutic or immunoprophylactic approach to cancer.
Materials and Methods
Cells and Cell Culture. Psi-CRE, J774G8 0774; reference 21) cells and its transfected derivates (J774-vector and J774-hsp65) were maintained in DME with 10% newborn calf serum. Wehi 164 and Pu518 cells were maintained in RPMI 1640 with 12% FCS. All media contained 100 #g/ml streptomycin, 100 #g/ml penicillin, 1 mM t-glutamine, and 10 mM Hepes.
Transfection ofJ774 cells with the Mycobacterium leprae hsp65
Gene. The transfection was carried out as described previously (22, 23 CD4 and CD8 T cell subsets were purified as described previously (24) . Briefly, NK, CD4, and/or CD8 cells were removed by treatment of cells (10Vml) with 10 #g/ml PK136 (anti-NKl.1; PharMingen) and anti-L3T4 and/or anti-Lyt-2 (Becton Dickinson & Co.) mAbs at 4~ for 30 min, followed by incubation with a 1:10 dilution of rabbit complement at 37~ for 60 min, resulting in CD4 and CD8 populations that were >90% pure as judged by FACS | analysis. To measure cytotoxic activity, varying numbers of CD4 or CD8 effector cells were incubated with 2,000 target cells per well labeled with nCr in triplicate wells for 6 h at 37~ in a V-bottomed 96-well microtiter plate. 51Cr release was measured in wells containing effector T cells and target cells (cp~), wells containing target cells incubated in medium alone (cprch~o~,), and in wells containing target cells plus 0.1% Triton X-100 (cpmm,~). Percent cytotoxicity was calculated using the formula: 100x[(cprn~w~=t,~ -cpmspon,,~,/(Cpmm,m~ --cpm,pon~o~)]. Target cells 0774-hsp65, J774, Pu518, or Wehi 164) were labeled with 51Cr by incubating 106 cells with 3.7 MBq of SlCr in 0.5 ml RPMI containing 20% FCS for 2 h, then washing three times.
Results and Discussion
The murine macrophage tumor cell line J774 was transfected with the M. leprae hsp65-encoding gene as previously described (22, 23) . Expression of the bacterial hsp was confirmed using mAbs directed to the bacterial hsp (not shown). J774 is a BALB/c-derived cell line; the tumorigenicity of the parent 0774) cell line and the hsp-transfected (J774-hsp65) cells was tested in euthymic and athymic BALB/c and in CBA mice. Euthymic BALB/c mice that received either the J774 cell line or the J774 cell line transfected with vector alone (J774-vector) developed tumors within 3 wk when given 106 cells (Table 1 and Fig. 1 ). These were large, highly malignant lymphoreticular neoplasms composed of histiocytic cells with many mitoses and cellular pleomorphisms with metastases in the spleen, liver, kidney, mesentery, and lung. In an attempt to identify the underlying mechanism for their loss of tumorigenicity, J774-hsp65 cells were compared with the parent cell line for differences in in vitro growth rate, expression of MHC class I and II molecules, and a variety of cell markers (including Fc and C3b receptor, LFA-1, CD44, and p53) thought to play a role in cellular interactions, tumorigenicity, or metastatic potential, and for expression of cytokine genes. There was elevated intracellular expression of p53 in the hsp-transfected cells (data not shown). Lost tumorigenicity of the transfected cells could result from the interaction of the hsp with p53, the protein encoded by the p53 tumor suppressor gene. Mutations in the p53 gene resulting in dysfunctional p53 protein are the most frequently observed genetic lesions in tumors (25) . P53 is a DNA-binding protein essential for normal cell cycle control, and hsp chaperones play a crucial role in its conformation and function (26, 27) . Thus, the increased efficiency of chaperone activity in the hsp-65-transfected cells could result in the proper folding and conformation of ineffective p53 protein, thereby correcting its loss of tumor suppressor function. The association be-iil + 
Growth of transfected tumor cells in normal (A) and athymic (B) BALB/c mice. Tumor cells were either the parent J774 cells ([])
, the parent cell line transfected with vector alone (J774-vector) ( 9 or the parent cell line transfected with the mycobacterial hsp65 gene (J774-hsp65) (II). Mice were injected intraperitoneally with 106 cells, and tumor size was calculated by weighing the primary tumor and abdominal organs of the test mice and subtracting the weight of abdominal organs of five agematched normal controls. For each cell type, 20 mice were inoculated. Hve mice were killed on days 7 and 14, and 10 on day 21. tween loss of tumorigenicity and elevated p53 expression is currently being investigated.
We next investigated whether mice that had received the transfected J774 cells showed any level of protection against developing tumors when challenged with the parent cell line. The results (Table 2 and Fig. 2) demonstrate a highly significant level of protection; J774 produced tumors in naive mice, but not in mice that had previously been immunized with J774-hsp65 cells. This was confirmed by autopsy and histological examination in which no evidence of tumor cells or autoimmune inflammation could be found. A second group of challenged mice were completely healthy 6 mo after challenge, and 80% have survived for >12 mo. The protection generated by J774-hsp65 cells appeared to be mediated by T cells, since immunized athymic mice all developed tumors after subsequent challenge.
To investigate the specificity of the protective effect, immunized mice were chaUenged with two other cell lines: Pu518, which is an unrelated, spontaneous reticulum sarcoma of BALB/c origin, and Wehi 164 cells, derived from a methyl cholanthrene-induced BALB/c sarcoma. The results ( Table  2 and Fig. 2 ) show significant protection against challenge with Pu518, but not with Wehi 164 cells. When mice were immunized with irradiated J774 cells they were partially protected against subsequent challenge (Table 2 ). This indicates that J774 cells do have tumor-associated antigens that normally do not induce an effective immune response; the presence of the 65-kD hsp in transfected cells presumably enhances this response.
Since protection appeared to be T cell mediated, we investigated the relationship between protection in vivo and T cell-mediated cytotoxicity in vitro. Nonadherent spleen cells from mice immunized with J774-hsp65 cells were cultured in vitro with irradiated J774-hsp65 cells for 6 d. Purified populations of CD4 or CD8 T cells were tested for cytotoxicity using J774, J774-hsp65, Pu518, and Wehi 164 cells as targets (Figs. 3 and 4) . Both CD4 and CD8 populations were highly cytotoxic for J774-hsp65 and for the parent J774 cells; deple- 
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Ratio of Effector Cells to Target Cells tion of both CD4 and CD8 cells resulted in elimination of cytotoxic activity (Fig. 3) , confirming that it was T cell mediated. CD4 and CD8 cells were also cytotoxic, although to a lesser degree, against Pu518, but not against Wehi 164 cells. Attempts to generate cytotoxic T cells from naive mice or from mice injected with J774 parent cells by in vitro stimulation with irradiated J774 cells failed, as insufficient T cells were obtained after the 6 d of in vitro stimulation. Thus, there appears to be a complete correlation between in vivo protection and the generation of cytolytic T cells capable of lysing these malignant reticulum sarcoma cells. We assume that the highly immunogenic nature of the 65-kD molecule provides greatly enhanced, associated recognition of other, tumor-associated antigen(s). The use of a highly antigenic molecule such as purified protein derivative (PPD) (which contains the 65-kD hsp) to greatly enhance immune responses to associated antigens has been demonstrated previously (28, 29) , and more recently the same effect has been achieved with recombinant mycobacterial hsp's (15, 16) . As with superantigens, a genuine primary recognition of hsp65 has been reported. T cells from PPD-negative individuals (30) , and from umbilical cord blood (31) , are stimulated by the mycobacterial hsp65. In our experiments (data not shown), splenocytes from naive BALB/c mice do not proliferate in response to J774 cells, but do so strongly in response to J774-hsp65 cells, indicating a substantial change in the immunogenic properties of the cells after transfection with hsp65. The finding of crossprotection against an unrelated reticulum sarcoma, Pu518, suggests the presence of shared antigens on the two unrelated sarcomas. Shared tumorassociated antigens have been found in human mdanomas (32) and murine sarcomas (33) . Endogenous expression of the bacterial hsp65 appears to be essential for protection; BALB/c mice immunized with four weekly injections of 50 #g recombinant hsp65 (rhsp65) all developed large intraabdominal tumors within 3 wk of challenge with J774 or J774-vector cells (data not shown). Similarly, preincubation ofJ774 cells with 50 #g/ml rhsp65 for 60 min, or injection of 50 #g of PPD as an adjuvant with J774 cells, failed to produce protection (data not shown).
Our results clearly show that transfection of the tumor cells with the bacterial hsp65 results in the induction of immunity against the parent tumor cell line; this immunity is reflected in the generation of cytotoxic T cells and protective immunity against the parent tumor. There is a great deal of current interest in the use of gene transfer, for example, of IL-2-or TNF-encoding genes, to increase the immunological recognition of cancer cells (19, 20) . The rapid progress that is being made on in vivo transfection, and the targeting of transgene expression to tumor cells (34) , could provide a role for the hsp65 gene in such an approach.
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